Literature DB >> 18070994

Influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes.

Jaco Voorham1, Flora M Haaijer-Ruskamp, Ronald P Stolk, Bruce H R Wolffenbuttel, Petra Denig.   

Abstract

Undertreatment of risk factors in patients with type 2 diabetes is common. We assessed the influence of elevated levels of blood pressure, total cholesterol, and A1C on decisions of Dutch general practitioners to change drug treatment in a cohort of 3,029 patients during a 1-year period. Respectively, 58, 71, and 21% of patients remained untreated despite poor blood pressure, lipid levels, and glycemic control. Of poorly controlled but already drug-treated patients, 52% did not receive intensification for antihypertensive medication, 81% not for lipid-lowering medication, and 43% not for glucose-lowering medication. We observed a significantly lower treatment intervention rate in moderately than in poorly controlled patients for blood pressure. This was not seen for decisions on cholesterol or A1C results. The low overall action rates observed for blood pressure and especially lipid management cannot sufficiently be explained by the use of treatment thresholds higher than those indicated by guidelines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070994     DOI: 10.2337/dc07-1043

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness.

Authors:  Grigory Sidorenkov; Flora M Haaijer-Ruskamp; Dick de Zeeuw; Petra Denig
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

2.  Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus--a cohort study.

Authors:  Jaco Voorham; Flora M Haaijer-Ruskamp; Bruce H R Wolffenbuttel; Dick de Zeeuw; Ronald P Stolk; Petra Denig
Journal:  PLoS One       Date:  2012-06-05       Impact factor: 3.240

3.  Change in cardio-protective medication and health-related quality of life after diagnosis of screen-detected diabetes: Results from the ADDITION-Cambridge cohort.

Authors:  J A Black; G H Long; S J Sharp; L Kuznetsov; C E Boothby; S J Griffin; R K Simmons
Journal:  Diabetes Res Clin Pract       Date:  2015-04-23       Impact factor: 5.602

4.  Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?

Authors:  Grigory Sidorenkov; Jaco Voorham; Dick de Zeeuw; Flora M Haaijer-Ruskamp; Petra Denig
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

5.  Effectiveness of shared goal setting and decision making to achieve treatment targets in type 2 diabetes patients: A cluster-randomized trial (OPTIMAL).

Authors:  Henk Den Ouden; Rimke C Vos; Guy E H M Rutten
Journal:  Health Expect       Date:  2017-05-24       Impact factor: 3.377

6.  Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study.

Authors:  Elisabeth AB; Petra Denig; Ton van Vliet; Janny H Dekker
Journal:  BMC Fam Pract       Date:  2009-04-21       Impact factor: 2.497

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.